Drug Profile
ELN 30
Alternative Names: ELN/30Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Elasmogen; Feldan Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Unspecified in Canada
- 28 Jan 2021 No recent reports of development identified for research development in Unspecified in United Kingdom
- 29 May 2018 Feldan Therapeutics has patent protection for the second generation of Feldan Shuttle platform in USA